United States

United States

ICAP’s two centers in New York, the Harlem Prevention Center and the Bronx Prevention Center, are hubs of research and service delivery in two areas of the city that have been historically underserved and disproportionately impacted by the HIV epidemic. ICAP works with local community-based organizations, community boards, political groups, religious leaders, and advocates to engage vulnerable populations in HIV testing, care, and treatment. Current studies include investigations of antibody-mediated prevention and injectable pre-exposure prophylaxis (PrEP).



2018Global HIV Implementation Science Research Fellowship (T32)United States

2018HPTN 076: Phase II Safety and Acceptability of Injectible Rilpivirine for PrEPUnited States

2018HVTN 704/HPTN 085: Antibody Mediated Prevention (Amp Study)United States

2018Minority Health and Health Disparities International Research Training Fellowship (MHIRT) (T37)United States

2018PrEPared & StrongUnited States


2018HPTN 067: Alternative Dosing to Augment Pre-Exposure Prophylaxis Pill Taking (The ADAPT Study)United States

2018In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal ProductsUnited States

2018MTN-014: Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% GelUnited States

ICAP IN the United States

Program Start


Key Technical Areas
  • HIV prevention, care, and treatment
  • Research Key populations
Current Funders
  • Baylor College of Medicine
  • Family Health International 360
  • PEPFAR / Health Resources & Services Administration (HRSA)
  • Indiana University
  • Joan & Sanford I. Weill Medical College of Cornell University
  • Johns Hopkins University
  • Mailman School of Public Health
  • Massachusetts General Hospital
  • National Institutes of Health
  • New York University
  • Pennsylvania State
  • University Research Foundation for Mental Hygiene
  • Trustees of Columbia University in the City of New York
  • University of Cape Town



ICAP founder and global DIRECTOR

Dr. Wafaa El-Sadr, MD, MPH, MPA

Wafaa El-Sadr is the founder and director of ICAP and an international expert in epidemiology and research on the prevention and management of HIV, tuberculosis, and other infectious diseases. For over three decades, she has advocated for families and communities most impacted by HIV and championed a collaborative, multidisciplinary approach to confronting the global epidemic. Based at Columbia University, she leads ICAP’s portfolio of projects in 21 countries and manages a global team of over 1,000 staff. Under her leadership, ICAP has become a global leader in HIV and health systems strengthening. She is also the director of the Mailman School’s Global Health Initiative (GHI), which mobilizes the University community to address critical challenges in global health. Dr. El-Sadr began her career as the HIV epidemic took hold in the United States. Read More